Pharmacologic Efficacy in Still's Disease Save
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
A metanalysis was performed using databases, trial registries, conference abstracts and published papers between 2012 and 2023, to assess outcomes discontinuation of treatments, complications, and treatment-related adverse events.
A total of 44 studies assessed the value of NSAIDs corticosteroids (CS), conventional synthetic DMARDS, biologic DMARDs [including tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK)].
Three randomized controlled trials did not show statistically significant benefits of bDMARDs, but metaanalyses showed high remission and CS discontinuation rates. Specifically for each drug:
| TCZ | ANK | CNK | |
| Remission | 80% | 73% | 77% |
| Steroid D/C | 57% | 47% | 34% |
These data supports the use of either TCZ, ANK, and CNK therapy for AOSD. Yet the magnitude of effect and comparative effectiveness of treatments is uncertain.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.